Drug Updates

Michele Kaufman is a freelance medical writer based in New York City and a clinical pharmacist at New York Downtown Hospital.

References

1. Ryan C, Leonardi CL, Kreuger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: A meta-analysis of randomised controlled trials. JAMA. 2011;306:864-871.
2. U.S. Food and Drug Administration. The Food and Drug Administration (FDA) Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM270958.pdf. Published September 9, 2011. Accessed October 10, 2011.
3. Wilson D. F.D.A. Staff: 5 years may be enough for bone drugs. http://prescriptions.blogs.nytimes.com/2011/09/07/f-d-a-staff-5-years-may-be-enough-for-bone-drugs/?emc=eta1. Published September 7, 2011. Accessed September 21, 2011.
4. Gever J. FDA warns against high-dose citalopram. www.medpagetoday.com/Psychiatry/Depression/28180. Published August 24, 2011. Accessed September 21, 2011.
5. U.S. Food and Drug Administration. Celexa (citalopram hydrobromide): Drug Safety Communication – Abnormal heart rhythms associated with high doses. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm269481.htm. Published August 24, 2011. Accessed September 21, 2011.
6. U.S. Food and Drug Administration. Arava (leflunomide) tablets. www.fda.gov/Safety/MedWatch/SafetyInformation/ucm230245.htm. Published July 2011. Accessed September 21, 2011.
7. Arava prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2011/020905s022lbl.pdf. Published July 8, 2011. Accessed September 21, 2011.
8. Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141:1314-1322.
9. Prograf label. www.accessdata.fda.gov/drugsatfda_docs/label/2011/050708s036s037,050709s028s030lbl.pdf. Published July 14, 2011. Accessed September 21, 2011
10. Lowes R. TNF blockers get boxed warning on 2 bacterial infections. www.medscape.com/viewarticle/749273?sssdmh=dm1.716535&src=nl_newsalert. Published September 7, 2011. Accessed September 21, 2011.
11. DeNoon DJ. Rheumatoid arthritis drugs may have small skin cancer risk – Study shows TNF inhibitors have no increased risk of other cancers. www.webmd.com/rheumatoid-arthritis/news/20110907/rheumatoid-arthritis-drugs-may-have-small-skin-cancer-risk?src=RSS_PUBLIC. Published September 7, 2011. Accessed September 21, 2011.
12. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis. Ann Rheum Dis. 2011;70:1895-1904.
13. Amari W, Zeringue L, McDonal JR, Caplan L, Eisen SA, Ranganathan P. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology. 2011;50:1431-1439.
14. Gever J. Reclast gets FDA kidney failure warning. www.medpagetoday.com/ProductAlert/Prescriptions/28320?utm_source=breaking-news&utm_medium=email&utm_campaign=breaking-news#.Tl_iQUUbywI.email. Published September 1, 2011. Accessed September 21, 2011.
15. NUCYNTA® ER (Tapentadol Extended-Release Tablets) receives FDA approval for the management of moderate to severe chronic pain. www.marketwatch.com/story/nucynta-er-tapentadol-extended-release-tablets-receives-fda-approval-for-the-management-of-moderate-to-severe-chronic-pain-2011-08-26. Published August 26, 2011. Accessed September 21, 2011.
16. Dane L. EU regulators approve Roche’s RoActemra for juvenile arthritis. www.firstwordpharma.com/node/895069. Published August 3, 2011. Accessed September 21, 2011.
17. Novartis present positive data from trial of Ilaris in SJIA. www.firstwordpharma.com/node/907942. Published September 19, 2011. Accessed September 21, 2011.